Biofluid Biomarkers in the Prognosis of Amyotrophic Lateral Sclerosis: Recent Developments and Therapeutic Applications.

Of note, nevertheless, a favorable trend was observed in secondary and exploratory clinical outcome measures that became more marked in the open-label extension study with longer term follow-up, particularly with earlier tofersen initiation [ 34 ].

also in 993 other papers